Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125370371 | 12537037 | 1 | I | 2011 | 20160614 | 20160707 | 20160707 | PER | US-PFIZER INC-2016301342 | PFIZER | 79.00 | YR | M | Y | 118.00000 | KG | 20160707 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125370371 | 12537037 | 1 | PS | NEURONTIN | GABAPENTIN | 1 | Oral | 300 MG, DAILY | N | 20235 | 300 | MG | |||||||
| 125370371 | 12537037 | 2 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 2000 MG, DAILY | N | 20235 | 2000 | MG | |||||||
| 125370371 | 12537037 | 3 | C | LASIX | FUROSEMIDE | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | QD | |||||||
| 125370371 | 12537037 | 4 | C | TAMULOSIN | TAMSULOSIN | 1 | Oral | 0.4 MG, 1X/DAY | 0 | .4 | MG | CAPSULE | QD | ||||||
| 125370371 | 12537037 | 5 | C | FINASTERIDE. | FINASTERIDE | 1 | Oral | 5 MG, 1X/DAY | 0 | 5 | MG | QD | |||||||
| 125370371 | 12537037 | 6 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 100 MG, 1X/DAY | 0 | 100 | MG | QD | |||||||
| 125370371 | 12537037 | 7 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Oral | 1 MG, 1X/DAY | 0 | 1 | MG | QD | |||||||
| 125370371 | 12537037 | 8 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | QD | |||||||
| 125370371 | 12537037 | 9 | C | BABY ASPIRIN | ASPIRIN | 1 | Oral | 81 MG, 1X/DAY | 0 | 81 | MG | QD | |||||||
| 125370371 | 12537037 | 10 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | QD | |||||||
| 125370371 | 12537037 | 11 | C | METOPROLOL. | METOPROLOL | 1 | Oral | 25 MG, 2X/DAY | 0 | 25 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125370371 | 12537037 | 1 | Pain in extremity |
| 125370371 | 12537037 | 3 | Fluid retention |
| 125370371 | 12537037 | 4 | Prostatomegaly |
| 125370371 | 12537037 | 5 | Prostatomegaly |
| 125370371 | 12537037 | 6 | Gout |
| 125370371 | 12537037 | 7 | Thyroid disorder |
| 125370371 | 12537037 | 8 | Gastrooesophageal reflux disease |
| 125370371 | 12537037 | 10 | Blood cholesterol increased |
| 125370371 | 12537037 | 11 | Hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125370371 | 12537037 | Breast pain | |
| 125370371 | 12537037 | Condition aggravated | |
| 125370371 | 12537037 | Gynaecomastia | |
| 125370371 | 12537037 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125370371 | 12537037 | 1 | 2011 | 2013 | 0 | |
| 125370371 | 12537037 | 2 | 2013 | 2013 | 0 | |
| 125370371 | 12537037 | 4 | 2011 | 0 | ||
| 125370371 | 12537037 | 5 | 2011 | 0 | ||
| 125370371 | 12537037 | 8 | 2013 | 0 | ||
| 125370371 | 12537037 | 10 | 200509 | 0 | ||
| 125370371 | 12537037 | 11 | 2005 | 0 |